MyFinsight
Home
Blog
About
Contact
Proceeds from issuance of
common stock upon...
$226,730K
Proceeds from issuance of
common stock under...
$5,236K
Exercise of warrants
$57K
Maturities of marketable
securities
$383,886K
Net cash provided by
financing activities
$238,744K
Net cash provided by
(used in) investing...
$172,615K
Canceled cashflow
$211,271K
Net increase
(decrease) in cash, cash...
$57,194K
Canceled cashflow
$354,165K
Stock-based compensation
expense
$87,299K
Accounts payable
$16,857K
Change in fair value of
warrant liability
$15,788K
Non-cash interest
expense on liabilities...
$12,197K
Other noncurrent
liabilities
$5,664K
Depreciation and
amortization
$2,346K
Amortization of operating
lease right-of-use...
$2,189K
Other prepaid and
noncurrent assets
$378K
Purchases of marketable
securities
$209,733K
Purchases of property and
equipment
$1,538K
Net cash used in
operating activities
-$354,165K
Canceled cashflow
$142,718K
Net loss
-$453,816K
Accrued expenses and
other current...
-$16,739K
Long-term deposits
$10,561K
Prepaid expenses and
other current assets
$10,471K
Net amortization of
premium or discount on...
$3,223K
Operating lease liability
-$2,073K
Back
Back
Cash Flow
Revolution Medicines, Inc. (RVMDW)
Revolution Medicines, Inc. (RVMDW)
source: myfinsight.com